⌕
Agios Pharmaceuticals · AGIO · Nasdaq
Tenet 64 · Solid
Compare
$30.15−4.56%At closeTenet 64 · Solid
$30.15−1.44 (−4.56%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Agios Pharmaceuticals (AGIO) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 7, 2026 · 09:44 ETEARNINGS EXPECTED BY FEB 16
Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript

Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Morgan Sanford - Vice President of Investor Relations Brian Goff - CEO & Director Cecilia Jones - Chief Financi…

● MarketBeatNov 5, 2026 · 12:15 ETEARNINGS EXPECTED BY FEB 16
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call

Agios Pharmaceuticals NASDAQ: AGIO reported record third-quarter product revenue as its thalassemia drug AQVESME continued its U.S. launch, while the company prepares for a delayed regulatory decision on the drug's use i…

● Zacks Investment ResearchNov 5, 2026 · 09:16 ETEARNINGS EXPECTED BY FEB 16
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.78 per share a year ago.…

● GlobeNewsWireNov 5, 2026 · 06:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update

Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. demand for AQVESME in th…

● GlobeNewsWireNov 4, 2026 · 09:01 ETCOMPANY'S OWN WORDS
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026

Agios announces new clinical data across company's rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.…

● Seeking AlphaOct 30, 2026 · 14:27 ET
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)

Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. Mitapivat's efficacy in SCD is mixed—endpoint for pain crises not met, but strong reduc…

● GlobeNewsWireOct 30, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios' response to the information request as a major amendment to the mitapivat s…

● Zacks Investment ResearchOct 29, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 16
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● GlobeNewsWireOct 8, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, tod…

● Zacks Investment ResearchOct 6, 2026 · 11:56 ET
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.…

● Zacks Investment ResearchOct 2, 2026 · 11:25 ET
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.…

● Defense WorldSep 4, 2026 · 03:26 ETEARNINGS EXPECTED BY FEB 16
Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO

Bank of New York Mellon Corp purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commi…

● Seeking AlphaAug 20, 2026 · 09:07 ETEARNINGS EXPECTED BY FEB 16
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel

Agios is leveraging mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026 mitapivat revenue to …

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just AGIO · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.